Shares of Blue Jet Healthcare surged more than 15% across the last two trading sessions, extending gains on Tuesday after rallying nearly 10% in the previous session, even as the company reported a sharp decline in Q4 FY26 earnings.
At around 9:29 AM on May 26, Blue Jet Healthcare shares were trading 6.45% higher at Rs 512.45 on the NSE. The stock has now gained over 15% since the Q4 earnings announcement.
Investor sentiment appeared to remain positive after the company’s board approved a proposal to raise up to Rs 1,000 crore through equity shares or other eligible instruments. The fundraising may be carried out through qualified institutional placement (QIP), rights issue, or other permissible routes, subject to shareholder and regulatory approvals.
The proposed capital raise came despite a weak operational performance during the March quarter.
Blue Jet Healthcare reported Q4 FY26 revenue from operations of Rs 234.67 crore, down 31.1% year-on-year from Rs 340.45 crore. Net profit declined 41.6% to Rs 64.34 crore compared to Rs 110.10 crore in Q4 FY25. Profit before tax fell 40.8% to Rs 87.15 crore.
For the full financial year FY26, the company reported revenue from operations of Rs 947.32 crore, an 8% decline from Rs 1,029.99 crore in FY25. Full-year net profit dropped 18.8% to Rs 247.82 crore from Rs 305.20 crore in the previous year.
| Metric | Q4 FY26 | Q4 FY25 | YoY Change |
|---|---|---|---|
| Revenue from Operations | Rs 234.67 crore | Rs 340.45 crore | -31.1% |
| Total Income | Rs 257.59 crore | Rs 352.67 crore | -26.9% |
| Profit Before Tax | Rs 87.15 crore | Rs 147.21 crore | -40.8% |
| Net Profit | Rs 64.34 crore | Rs 110.10 crore | -41.6% |
| Basic EPS | Rs 3.71 | Rs 6.35 | -41.6% |
Blue Jet Healthcare operates in the specialty pharmaceutical segment with focus areas including contrast media intermediates and high-value active pharmaceutical ingredients (APIs). Market participants are likely viewing the proposed fundraising as a move that could strengthen the company’s balance sheet and support future expansion initiatives despite near-term earnings pressure.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.